Breast Cancer Clinical Trials in Philadelphia

Showing 261-280 of 391 trials

Optoacoustic Images Versus Imagio® Ultrasound

NCT04030104

The Imagio® Pivotal Study is intended to evaluate if the results observed in the previous Feasibility Study can be confirmed for pre-specified effectiveness endpoints. Using Intention-to-Diagnose (ITD) masses from the PIONEER Pivotal study, 480 to 840 masses are to be used for the Pivotal Study, the remaining masses will be reserved for training the SenoGram® model.

Breast Cancer

Seno Medical Instruments Inc.480 participantsStarted Jul 2019

Philadelphia, Pennsylvania, United States

TERMINATEDPHASE1/PHASE2< 1 mile

Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

NCT03983395

The purpose of this study is to determine the safety profile, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single agent ISB1302 in subjects with HER2-positive metastatic breast cancer who have been treated with all known therapies known to confer clinical benefit.

Breast Cancer

Ichnos Sciences SA1 participantsStarted Apr 2020

Gilbert, Arizona, United States • Los Angeles, California, United States • Louisville, Kentucky, United States +2 more locations

Optoacoustic Images Versus Imagio® Ultrasound

Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

Breast Cancer Trials in Other Cities

Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy

Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

PCA062 in pCAD-positive Tumors.

Other Conditions in Philadelphia